Header Logo

Connection

Sonal Singh to Pulmonary Disease, Chronic Obstructive

Back to Details
This is a "connection" page, showing publications Sonal Singh has written about Pulmonary Disease, Chronic Obstructive.
Sonal Singh
Connection Strength
4.161
Pulmonary Disease, Chronic Obstructive
  1. Singh S, Loke YK, Enright P, Furberg CD. Republished: pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Postgrad Med J. 2014 Apr; 90(1062):205-7.
    View in: PubMed
    Score: 0.390
  2. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013 Jan; 68(1):114-6.
    View in: PubMed
    Score: 0.346
  3. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011 Jun 14; 342:d3215.
    View in: PubMed
    Score: 0.321
  4. Singh S, Furberg CD. Inhaled anticholinergics for chronic obstructive pulmonary disease: comment on "Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease". Arch Intern Med. 2011 May 23; 171(10):920-2.
    View in: PubMed
    Score: 0.320
  5. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011 Aug; 66(8):699-708.
    View in: PubMed
    Score: 0.320
  6. Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010 Aug 09; 5:189-95.
    View in: PubMed
    Score: 0.303
  7. Singh S, Loke YK, Furberg CD. Outpatient management of severe COPD. N Engl J Med. 2010 07 29; 363(5):493-4; author reply 494-5.
    View in: PubMed
    Score: 0.302
  8. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010 Mar; 16(2):118-22.
    View in: PubMed
    Score: 0.294
  9. Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010 May; 35(5):1003-21.
    View in: PubMed
    Score: 0.288
  10. Loke YK, Singh S. Inhaled corticosteroids in patients with chronic obstructive pulmonary disease. JAMA. 2009 Apr 08; 301(14):1432; author reply 1433-4.
    View in: PubMed
    Score: 0.276
  11. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009 Feb 09; 169(3):219-29.
    View in: PubMed
    Score: 0.273
  12. Singh S, Furberg CD, Loke YK. Tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2009 Jan 08; 360(2):186; author reply 187.
    View in: PubMed
    Score: 0.271
  13. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Sep 24; 300(12):1439-50.
    View in: PubMed
    Score: 0.266
  14. Loke YK, Singh S, Furberg CD. Tiotropium and the risk of death in COPD. N Engl J Med. 2014 01 30; 370(5):480-1.
    View in: PubMed
    Score: 0.096
  15. Yu T, Fain K, Boyd CM, Singh S, Weiss CO, Li T, Varadhan R, Puhan MA. Benefits and harms of roflumilast in moderate to severe COPD. Thorax. 2014 Jul; 69(7):616-22.
    View in: PubMed
    Score: 0.096
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.